fda compounding semaglutide crackdown september 2025 Hims & Hers Health addresses scrutiny of GLP-1 compounding| STAT FDA and Novo Nordisk Warned

TRIUMPH-1, the main obesity trial, followed 2,339 adults without diabetes for 80 weeks

Some people report fewer side effects when injecting into the thigh rather than the stomach, though clinical evidence on this is limited

Appetite Loss Reduced appetite is expected while taking a GLP-1 medication

[133] Attention deficit hyperactivity disorder [edit] Altered dopamine neurotransmission is implicated in attention deficit hyperactivity disorder (ADHD), a condition associated with impaired cognitive control, in turn leading to problems with regulating attention (attentional control), inhibiting behaviors (inhibitory control), and forgetting things or missing details (working memory), among other problems

Other medications in the GLP-1 class include liraglutide and tirzepatide (a dual-pathway medication that works on both GLP-1 and GIP receptors)

At Southern Care Anesthetics, our team utilizes BPC-157 to help patients recover faster from both acute and chronic conditions, supporting overall health and well-being